From Nature’s Potential to Pharmaceutical Reality

Pet Pharmaceuticals is pioneering a new therapeutic class of pharmaceutical-grade multi-pathway combination phytopharmaceutical medicines.

These are not supplements or traditional herbal products. They are differentiated prescription-medicine candidates designed through rigorous pharmaceutical science, with defined compositions, controlled quality, reproducible manufacturing and a disciplined pathway towards scientific and regulatory validation.

Why Multi-Pathway Combination Medicines?

Many chronic and complex diseases involve interacting biological mechanisms rather than a single isolated target. Medicines focused on one pathway may therefore provide incomplete benefit, generate treatment-limiting side effects or become less effective over time.

Our scientific approach brings together carefully selected bioactive compounds designed to act across complementary pathways. The objective is to address disease biology more comprehensively while creating the potential for improved efficacy, tolerability and long-term therapeutic value.

Our Integrated Scientific Discovery Capability

Our Integrated Scientific Discovery Capability combines the scientific disciplines, proprietary knowledge and development processes required to identify, optimise and progress differentiated pharmaceutical assets.

It brings together:

Natural-product science and phytochemistry
Pharmacology and systems biology
Formulation and pharmaceutical development
Protected scientific sources and proprietary knowledge
Advanced analytical technologies and data science
Intellectual-property development
Disciplined stage-gated programme governance

This integrated capability is designed to be repeatable, scalable and applicable across multiple disease areas.

PolyNexis+™ Discovery Platform

The proprietary PolyNexis+™ Discovery Platform is an enabling component within our wider scientific capability. It supports candidate identification, selection, optimisation and evidence-led decision-making.

AI and advanced data science strengthen this process by helping analyse complex relationships across compounds, pathways, disease biology and development data. They are enabling technologies within PolyNexis+™, not the platform or the investment proposition in isolation.

PolyNexis+™ transforms nature’s potential into pharmaceutical reality.

Our Discovery and Development Process

Discover

Identify high-potential natural-product sources, bioactive compounds and therapeutic opportunities.

Decode

Characterise biological activity, mechanisms, interactions and relevance to disease pathways.

Design

Create and optimise proprietary multi-pathway combination candidates with defined pharmaceutical objectives.

Develop

Advance selected candidates through formulation, analytical development, preclinical validation, manufacturing planning and regulatory preparation.

Deliver

Create partner-ready pharmaceutical assets for strategic licensing, co-development or asset monetisation.

Initial Therapeutic Portfolio

Parasiticides

Developing differentiated approaches to parasite control, with the objective of addressing efficacy, tolerability and emerging resistance challenges. The lead programme has completed in vitro efficacy studies and is progressing through the next stage of scientific evaluation.

Osteoarthritis

Exploring multi-pathway medicines designed to address pain, inflammation, mobility and long-term tolerability in a common chronic condition affecting companion animals.

Dermatitis

Developing candidates aimed at the interconnected inflammatory, immune and barrier mechanisms involved in chronic dermatological disease.

Oncology (Lymphoma)

Investigating multi-pathway therapeutic opportunities intended to complement the complex biology of lymphoma and support differentiated future treatment strategies.

Diabetes / Obesity

Targeting interconnected metabolic, inflammatory and endocrine pathways involved in chronic metabolic disease.

Anxiety

Exploring medicines designed to address multiple neurobiological and physiological pathways relevant to anxiety and behavioural health.

Disciplined, Stage-Gated Development

Each programme is advanced through defined scientific and commercial decision points. This stage-gated approach is designed to concentrate capital on the strongest opportunities, identify development risks early and build high-quality evidence packages for future partners.

The Company’s model is to Discover, Develop, Validate and Monetise through strategic partnerships, licensing, co-development and asset transactions.

A Repeatable and Defensible Scientific Capability

Our competitive advantage is not dependent on a single candidate or patent. It is created through the integration of the PolyNexis+™ Discovery Platform, proprietary nucleus product combinations, protected scientific sources and knowledge, disciplined development expertise and a growing intellectual-property portfolio.

This creates a repeatable capability capable of generating multiple pharmaceutical assets across therapeutic indications.

Creating Better Medicines

Our scientific objective is clear: to create safer, more effective medicines for chronic and complex diseases by addressing disease biology through complementary therapeutic pathways and rigorous pharmaceutical development.

Call Us Today